J. Kastelein

J. Kastelein, M. Koopman, Wim A. van der Steeg, 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Atorvastatin and the dyslipidemia of early renal failure.

J. Kastelein, M. Koopman, L. Arisz, 2003, Atherosclerosis.

Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of Bempedoic acid on cardiovascular events in patients with statin intolerance.

P. Libby, D. Grobbee, P. Thompson, 2020, American heart journal.

Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia.

J. Kastelein, R. Santos, J. Witztum, 2016, Journal of clinical lipidology.

Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.

J. Kastelein, P. Deedwania, N. Wenger, 2008, Journal of the American College of Cardiology.

Perturbation of hyaluronan metabolism predisposes patients with type 1 diabetes mellitus to atherosclerosis

J. Kastelein, M. Nieuwdorp, E. Stroes, 2007, Diabetologia.

Vascular disease: Meta-regression of CIMT trials—data in, garbage out

Allen J. Taylor, J. Kastelein, M. Bots, 2011, Nature Reviews Cardiology.

Long-term LDL-c lowering in heterozygous familial hypercholesterolemia normalizes carotid intima-media thickness.

J. Kastelein, S. Sivapalaratnam, M. Trip, 2010, Atherosclerosis.

The ENHANCE study and marketing ezetimibe.

D. Gaudet, J. Kastelein, F. Akdim, 2008, JAMA.

Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia.

J. Kastelein, M. Trip, E. Veltri, 2008, Journal of the American College of Cardiology.

Statin therapy for targeting cardiovascular risk in rheumatoid arthritis

J. Kastelein, P. Tak, E. Stroes, 2009 .

Effect of statin withdrawal on frequency of cardiac events after vascular surgery.

Jeroen J. Bax, J. Kastelein, R. V. van Domburg, 2007, The American journal of cardiology.

Apolipoprotein A-V, triglycerides and risk of coronary artery disease: the prospective Epic-Norfolk Population Study Published, JLR Papers in Press, June 12, 2006.

P. Talmud, M. Sandhu, R. Luben, 2006, Journal of Lipid Research.

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

P. Libby, P. Pais, J. Varigos, 2017, The Lancet.

The role of CETP inhibition in dyslipidemia

J. Kastelein, E. Stroes, K. Harchaoui, 2007, Current atherosclerosis reports.

Macular Degeneration and CETP Inhibition.

D. Rader, J. Kastelein, A. Tall, 2022, JAMA cardiology.

Elevated Remnant-Like Particles in Heterozygous Familial Hypercholesterolemia and Response to Statin Therapy

J. Kastelein, G. Dallinga-Thie, B. Hutten, 2002, Circulation.

Reduction of monocyte chemoattractant protein 1 and macrophage migration inhibitory factor by a polyphenol-rich extract in subjects with clustered cardiometabolic risk factors

Diederik F Van Wijk, J. Kastelein, W. Koenig, 2011, British Journal of Nutrition.

New Risk Factors for Atherosclerosis and Patient Risk Assessment

J. Kastelein, E. Stroes, J. Fruchart, 2004, Circulation.

Rapid, arteriovenous graft failure due to intimal hyperplasia: a porcine, bilateral, carotid arteriovenous graft model.

J. Kastelein, J. Blankensteijn, G. Pasterkamp, 2003, The Journal of surgical research.

Detection of liquid phase cholesteryl ester in carotid atherosclerosis by 1H-MR spectroscopy in humans.

Diederik F Van Wijk, J. Kastelein, R. Duivenvoorden, 2013, JACC. Cardiovascular imaging.

Effects of short-term and long-term danazol treatment on lipoproteins, coagulation, and progression of atherosclerosis: two clinical trials in healthy volunteers and patients with hereditary angioedema.

J. Kastelein, E. Stroes, M. Levi, 2008, Clinical therapeutics.

Ext1 heterozygosity causes a modest effect on postprandial lipid clearance in humans[S]

J. Kastelein, M. Nieuwdorp, J. Esko, 2015, Journal of Lipid Research.

Truncation mutations in ABCA1 suppress normal upregulation of full-length ABCA1 by 9-cis-retinoic acid and 22-R-hydroxycholesterol Published, JLR Papers in Press, August 16, 2002. DOI 10.1194/jlr.M200277-JLR200

A. Brownlie, M. Hayden, J. Kastelein, 2002, Journal of Lipid Research.

Is insulin the preferred compound in lowering glucose levels in patients after a myocardial infarction?

J. Kastelein, K. Rensing, M. Twickler, 2009, Archives of internal medicine.

Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk: A Secondary Analysis of the STRENGTH Trial.

D. Mozaffarian, P. Ridker, J. Kastelein, 2021, JAMA cardiology.

Effect of High-Dose Atorvastatin on Hospitalizations for Heart Failure Subgroup Analysis of the Treating to New Targets (TNT) Study Heart Failure

J. Kastelein, K. Khush, P. Deedwania, 2007 .

Compound heterozygosity for a known and a novel defect in the lipoprotein lipase gene (Asp250-->Asn; Ser251-->Cys) resulting in lipoprotein lipase (LPL) deficiency.

M. Hayden, J. Kastelein, G. Assmann, 1996, The Netherlands journal of medicine.

Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia.

J. Kastelein, E. Stroes, S. Tsimikas, 2005, Arteriosclerosis, thrombosis, and vascular biology.

−455G/A Polymorphism of the β-Fibrinogen Gene is Associated With the Progression of Coronary Atherosclerosis in Symptomatic Men

A. Zwinderman, J. Kastelein, J. Jukema, 1998 .

Lipoprotein Lipase Deficiency—Rare or Common?

J. Kastelein, Valerie Evans, 2002, Cardiovascular Drugs and Therapy.

Ezetimibe stimulates faecal neutral sterol excretion depending on abcg8 function in mice

J. Kastelein, A. Groen, F. Stellaard, 2010, FEBS letters.

Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels

J. Kastelein, S. Nicholls, A. Nelson, 2022, International journal of molecular sciences.

Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP Inhibition as a Strategy to Reduce Cardiovascular Risk: The Pro Case C ONTROVERSIES I N C ARDIOVASCUlAR M EDICINE

P. Barter, J. Kastelein, K. Rye, 2015 .

COMPARISON OF EFFECTS OF TORCETRAPIB AND RO4607381/JTT-705 ON BLOOD PRESSURE AND TISSUE EXPRESSION OF RENIN-ANGIOTENSIN SYSTEM-RELATED GENES IN RATS

J. Kastelein, E. Stroes, A. Bénardeau, 2008 .

7 lipoprotein lipase Gene polymorphisms and the risk of tarGet vessel revascularization after percutaneous coronary intervention

A. Zwinderman, R. J. Winter, J. Kastelein, 2006 .

Lipoprotein lipase gene polymorphisms and the risk of target vessel revascularization after percutaneous coronary intervention.

A. Zwinderman, R. D. de Winter, J. Kastelein, 2005, Journal of the American College of Cardiology.

n g l a d r n a l of m e d i c i n e Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

P. Libby, P. Pais, R. Glynn, 2017 .

Baseline lipid values partly determine the response to high-dose simvastatin in patients with familial hypercholesterolemia. The examination of probands and relatives in Statin studies with familial hypercholesterolemia (ExPRESS FH).

J. Kastelein, B. Hutten, P. R. W. de Sauvage Nolting, 2002, Atherosclerosis.

The prolactin receptor is expressed in macrophages within human carotid atherosclerotic plaques: a role for prolactin in atherogenesis?

J. Kastelein, P. Teeling, J. H. von der Thüsen, 2011, The Journal of endocrinology.

FISHing for the Miracle of Eicosapentaenoic Acid.

J. Kastelein, E. Stroes, 2019, New England Journal of Medicine.

217 IMPACT OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITION ON NUCLEAR MAGNETIC RESONANCE DERIVED LIPOPROTEIN PARTICLE PARAMETERS

J. Kastelein, S. Nissen, S. Nicholls, 2011 .

Cholesterol Acyltransferase Gene Mutations Have Accelerated Atherogenesis as Assessed by Carotid 3.0-T Magnetic Resonance Imaging Carriers

J. Kastelein, E. Groot, R. Duivenvoorden, 2011 .

Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I)

L. Deckelbaum, J. Kastelein, A. Lincoff, 2016 .

Novel lipid modifying drugs to lower LDL cholesterol

J. Kastelein, L. Reeskamp, A. Cupido, 2017, Current opinion in lipidology.

High-Density Lipoprotein Attenuates Inflammation and Coagulation Response on Endotoxin Challenge in Humans

T. van der Poll, J. Kastelein, E. Stroes, 2007, Arteriosclerosis, thrombosis, and vascular biology.

Activation of Inflammation and Coagulation After Infusion of C-Reactive Protein in Humans

P. Reitsma, J. Kastelein, E. Stroes, 2005, Circulation research.

A Head‐to‐Head Comparison of a Free Fatty Acid Formulation of Omega‐3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE‐IT Study

J. Kastelein, C. Ballantyne, H. Bays, 2022, Journal of the American Heart Association.

patient-oriented and epidemiological research Partial recovery of the endothelial glycocalyx upon rosuvastatin therapy in patients with heterozygous familial hypercholesterolemia

J. Kastelein, M. Nieuwdorp, E. Stroes, 2008 .

compounds: A meta-analysis of randomized controlled trials Efficacy and safety of high-density lipoprotein cholesterol-increasing

J. Kastelein, E. Stroes, B. Hutten, 2007 .

fficacy and Safety of High-Density ipoprotein Cholesterol-Increasing Compounds Meta-Analysis of Randomized Controlled Trials

J. Kastelein, B. Hutten, R. Birjmohun, 2004 .

6-455 G / a polymorphism and preprocedural plasma levels of fibrinoGen show no association with the risk of clinical restenosis in patients with coronary stent placement

A. Zwinderman, R. J. Winter, J. Kastelein, 2006 .

Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.

P. Ridker, G. Hitman, A. Gotto, 2014, Journal of the American College of Cardiology.

P.018 OPTIMIZATION OF ULTRASOUND BRACHIAL ENDOTHELIAL FUNCTION MEASUREMENTS

J. Kastelein, E. Groot, J. Deanfield, 2006 .

Pleiotropic effects of statins: stabilization of the vulnerable atherosclerotic plaque?

J. Kastelein, F. Akdim, E. Stroes, 2007, Current pharmaceutical design.

Achieving lipid goals in real life: the Dutch DISCOVERY Study

J. Kastelein, J. Kastelein, A. F. E. Bots, 2005, International journal of clinical practice.

Chapter 6 High-Density Lipoprotein Attenuates Infl ammation and Coagulation Response upon Endotoxin Challenge in Humans

J. Kastelein, S. I. V. Leuven, E. Stroes, 2009 .

Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.

D. Gaudet, J. Kastelein, D. Brisson, 2015, The New England journal of medicine.

Can we revive CETP-inhibitors for the prevention of cardiovascular disease?

J. Kastelein, K. Ray, Stephen J. Nicholls, 2022, Current opinion in lipidology.

Letter to the Editor In response to van den Berg et al

J. Kastelein, E. Stroes, R. Bisoendial, 2005 .

Carotid and femoral B-mode ultrasound intima-media thickness measurements in adult post-coarctectomy patients.

J. Kastelein, B. Mulder, J. Vriend, 2004, International angiology : a journal of the International Union of Angiology.

Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?

J. Kastelein, N. Nurmohamed, M. Ditmarsch, 2021, Cardiovascular Research.

Two-year efficacy and safety of simvastatin 80 mg in familial hypercholesterolemia (the Examination of Probands and Relatives in Statin Studies With Familial Hypercholesterolemia [ExPRESS FH]).

J. Kastelein, B. Hutten, P. R. W. de Sauvage Nolting, 2002, The American journal of cardiology.

Rate of change in carotid intima–media thickness and vascular events: meta-analyses can not solve all the issues. A point of view

S. Peters, D. Grobbee, Allen J. Taylor, 2012, Journal of hypertension.

Monday, 27 August 2012

V. V. Ivanenko, E. A. Medvedeva, Michail I. Papafaklis, 2012 .

Lipid-lowering medications.

S. Daniels, J. Kastelein, M. N. Vissers, 2004, Pediatric endocrinology reviews : PER.

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

P. Libby, P. Pais, P. Ridker, 2017, The New England journal of medicine.

Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.

Ming-Dauh Wang, M. Shao, J. Kastelein, 2011, JAMA.

New Drugs for Atherosclerosis.

J. Kastelein, G. Hovingh, C. Bruikman, 2017, The Canadian journal of cardiology.

Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week clinical trial.

J. Kastelein, D. Orloff, R. Vige, 2016, Journal of clinical lipidology.

Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia.

D. Rader, J. Kastelein, Daniel J Rader, 2014, Circulation.

Antisense oligonucleotides for the treatment of dyslipidaemia.

J. Kastelein, J. Witztum, E. Stroes, 2012, European heart journal.

Prolactin does not affect human platelet aggregation or secretion.

J. Kastelein, R. Nieuwland, V. Goffin, 2009, Thrombosis and haemostasis.

Prolactin does not affect human platelet aggregation or secretion

J. Kastelein, R. Nieuwland, V. Goffin, 2009, Thrombosis and Haemostasis.

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.

B. Nordestgaard, J. Kastelein, K. Maki, 2014, Journal of clinical lipidology.

Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial.

M. Eriksson, J. Kastelein, M. Trip, 2010, Clinical therapeutics.

Nonpharmacological lipoprotein apheresis reduces arterial inflammation in familial hypercholesterolemia.

Diederik F Van Wijk, Z. Fayad, J. Kastelein, 2014, Journal of the American College of Cardiology.

Regression of carotid and femoral artery intima-media thickness in familial hypercholesterolemia: treatment with simvastatin.

A. Zwinderman, J. Kastelein, M. Trip, 2003, Archives of internal medicine.

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

R. Collins, S. Cosgrove, P. Libby, 2017, The Lancet.

Mendelian Randomization Study of ACLY and Cardiovascular Disease

J. Danesh, A. Wood, J. Kastelein, 2019, The New England journal of medicine.

Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo.

J. Kastelein, M. Nieuwdorp, F. Holleman, 2006, Diabetes.

Hepatic and Cardiovascular Consequences of Familial Hypobetalipoproteinemia

J. Kastelein, E. Stroes, E. de Groot, 2005, Arteriosclerosis, thrombosis, and vascular biology.

Effective Lipid-lowering Therapy in High-risk Patients

J. Kastelein, J. Tardif, B. Arsenault, 2011 .

Heterozygosity for a loss-of-function mutation in GALNT2 improves plasma triglyceride clearance in man.

A. Zwinderman, J. Seidman, L. Tabak, 2011, Cell metabolism.

C-reactive protein elicits white blood cell activation in humans.

J. Kastelein, F. Akdim, E. Stroes, 2009, The American journal of medicine.

Increased risk of coronary artery disease in Caucasians with extremely low HDL cholesterol due to mutations in ABCA1, APOA1, and LCAT.

M. Hayden, J. Kastelein, I. Tietjen, 2012, Biochimica et biophysica acta.

Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes.

R. Heine, J. Kastelein, M. Nieuwdorp, 2006, Diabetes.

High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies.

Christina Lindahl, Nicholas J Wareham, Mogens Lytken Larsen, 2008, Journal of the American College of Cardiology.

Controversies in cardiovascular medicine C-reactive protein is a mediator of cardiovascular disease

J. Kastelein, S. Boekholdt, E. Stroes, 2010 .

The dyslipidemia of chronic renal disease: effects of statin therapy

J. Kastelein, S. V. van Leuven, M. Koopman, 2006, Current opinion in lipidology.

Lipid Measures and Cardiovascular Disease Prediction

Diederik F Van Wijk, J. Kastelein, E. Stroes, 2009, Disease markers.

The endothelial glycocalyx: a potential barrier between health and vascular disease

Hans Vink, Max Nieuwdorp, Joost B L Hoekstra, 2005, Current opinion in lipidology.

Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile

B Clotet, J J Kastelein, F. van Leth, 2001, AIDS.

Lipid‐Reduction Variability and Antidrug‐Antibody Formation with Bococizumab

P. Ridker, R. Glynn, J. Kastelein, 2017, The New England journal of medicine.

Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosis.

Diederik F Van Wijk, M. Hayden, J. Kastelein, 2010, Atherosclerosis.

Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing?

J. Kastelein, J. Hoekstra, J. H. von der Thüsen, 2011, Diabetes, obesity & metabolism.

Assessment of atherosclerosis: the role of flow-mediated dilatation.

J. Kastelein, T. Lüscher, J. Deanfield, 2010, European heart journal.

ABCG5/G8 polymorphisms and markers of cholesterol metabolism: systematic review and meta-analysis[S]

J. Kastelein, G. Dallinga-Thie, M. Tanck, 2010, Journal of Lipid Research.

Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis

J. Kastelein, E. Stroes, S. Tsimikas, 2020, Current Atherosclerosis Reports.

Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.

J. Kastelein, S. V. van Deventer, S. Warrington, 2014, British journal of clinical pharmacology.

Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk?Response to Barter et al

P. Barter, J. Kastelein, K. Rye, 2015 .

Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP Inhibition as a Strategy to Reduce Cardiovascular Risk: The Pro Case.

P. Barter, J. Kastelein, K. Rye, 2015, Circulation.

High-density lipoprotein: A fall from grace?

J. Kastelein, E. Stroes, S. V. van Leuven, 2008, Annals of medicine.

A review of CETP and its relation to atherosclerosis Published, JLR Papers in Press, September 1, 2004. DOI 10.1194/jlr.R400007-JLR200

J. Kastelein, E. Stroes, A. Stalenhoef, 2004, Journal of Lipid Research.

Hormones and cardiovascular disease: a shift in paradigm with clinical consequences?

H. Büller, J. Kastelein, V. Gerdes, 2009, Seminars in thrombosis and hemostasis.

Pharmacogenetics of the CD14 endotoxin receptor polymorphism and progression of coronary atherosclerosis

A. Zwinderman, J. Kastelein, J. Jukema, 2004, Thrombosis and Haemostasis.

Role of lipoprotein lipase in triglyceride metabolism: potential therapeutic target

J. Kastelein, G. Dallinga-Thie, E. Stroes, 2008 .

The genetics of high-density lipoprotein metabolism: clinical relevance for therapeutic approaches.

J. Kastelein, E. Stroes, G. Hovingh, 2009, The American journal of cardiology.

Endothelial glycocalyx as potential diagnostic and therapeutic target in cardiovascular disease

Hans Vink, Max Nieuwdorp, J. Kastelein, 2009, Current opinion in lipidology.

Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk

Brian A Ference, John Danesh, Adam S Butterworth, 2017, JAMA.

Cholesteryl Ester Transfer Protein Inhibitor Torcetrapib and Off-Target Toxicity: A Pooled Analysis of the Rating Atherosclerotic Disease Change by Imaging With a New CETP Inhibitor (RADIANCE) Trials

D. Grobbee, J. Kastelein, M. Bots, 2008, Circulation.

The effect of CETP inhibitors on new-onset diabetes: a systematic review and meta-analysis

J. Kastelein, A. Navar, K. Dangas, 2022, European heart journal. Cardiovascular pharmacotherapy.

New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B: JACC Focus Seminar 1/4.

J. Kastelein, N. Nurmohamed, A. Navar, 2021, Journal of the American College of Cardiology.

Pre-procedural levels of erythrocyte sedimentation rate (ESR) and risk of clinical restenosis in patients with percutaneous coronary intervention and coronary stent placement

A. Zwinderman, R. J. Winter, J. Kastelein, 2005, Thrombosis and Haemostasis.

Effects of Gemfibrozil and Ciprofibrate on Plasma Levels of Tissue-type Plasminogen Activator, Plasminogen Activator Inhibitor-1 and Fibrinogen in Hyperlipidaemic Patients

J. Kastelein, T. Kooistra, C. Kluft, 1997, Thrombosis and Haemostasis.

Rationale and design of ApoA-I event reducing in ischemic syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction.

L. Deckelbaum, P. Ridker, S. Pocock, 2020, American heart journal.

–455 G/A polymorphism and preprocedural plasma levels of fibrinogen show no association with the risk of clinical restenosis in patients with coronary stent placement

A. Zwinderman, R. D. de Winter, J. Kastelein, 2005, Thrombosis and Haemostasis.

Genetic Disorders of the Lipoprotein Metabolism; Diagnosis and Management

J. Kastelein, L. Jakulj, A. Bakker, 2011 .

Designs of RADIANCE 1 and 2:carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis*

J. Kastelein, C. Shear, J. Revkin, 2007, Current medical research and opinion.

Raising high-density lipoprotein cholesterol for better prevention of cardiovascular disease

J. Kastelein, E. Stroes, R. Birjmohun, 2006 .

Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial

M. Shao, J. Kastelein, A. Lincoff, 2019, JAMA cardiology.

C-reactive protein and atherogenesis: from fatty streak to clinical event.

J. Kastelein, E. Stroes, R. Bisoendial, 2007, Atherosclerosis.

The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice.

N. Sattar, R. Erbel, J. Kastelein, 2014, Atherosclerosis. Supplements.

Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial.

B. Williams, G. Bakris, J. Kastelein, 2013, JAMA.

Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial

J. Kastelein, M. Trip, A. Nederveen, 2012, European heart journal.

Prevention and Epidemiology

J. Kastelein, M. Trip, A. Nederveen, 2022 .

Obesity and dyslipidemia.

J. Kastelein, E. Stroes, R. Franssen, 2011, The Medical clinics of North America.

Obesity and dyslipidemia.

J. Kastelein, E. Stroes, R. Franssen, 2008, Endocrinology and metabolism clinics of North America.

The role of the ABCA1 transporter and cholesterol efflux in familial hypoalphalipoproteinemia Published, JLR Papers in Press, April 16, 2003. DOI 10.1194/jlr.M300080-JLR200

A. Brownlie, M. Hayden, J. Kastelein, 2003, Journal of Lipid Research.

And then there were acyl coenzyme A:cholesterol acyl transferase inhibitors

J. Kastelein, M. C. Meuwese, E. Stroes, 2006, Current opinion in lipidology.

Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease.

J. Kastelein, P. Deedwania, A. Breazna, 2008, Mayo Clinic proceedings.

Intervention to improve adherence to lipid-lowering medication and lipid-levels in patients with an increased cardiovascular risk.

M. Sprangers, J. Kastelein, E. Stroes, 2012, The American journal of cardiology.

Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.

J. Kastelein, E. Stroes, Erik S G Stroes, 2005, Journal of the American College of Cardiology.

Lipid assessment, metabolic syndrome and coronary heart disease risk

J. Després, N. Wareham, J. Kastelein, 2010, European journal of clinical investigation.

Measurement of subclinical atherosclerosis: beyond risk factor assessment

J. Kastelein, E. Stroes, E. de Groot, 2002, Current opinion in lipidology.

High-dose statin monotherapy versus low-dose statin/ezetimibe combination on fasting and postprandial lipids and endothelial function in obese patients with the metabolic syndrome: The PANACEA study.

J. Kastelein, W. Spiering, B. Coll, 2013, Atherosclerosis.

Targeting cardiovascular risk in rheumatoid arthritis: a dual role for statins

J. Kastelein, P. Tak, E. Stroes, 2010, Nature Reviews Rheumatology.

Time to change the SCORE?

J. Kastelein, K. Ray, 2017, European heart journal.

Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction

L. Deckelbaum, J. Kastelein, A. Lincoff, 2016, Circulation.

Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses.

A. Zwinderman, D. Rader, J. Kastelein, 2016, Journal of clinical lipidology.

What does the future hold for cholesteryl ester transfer protein inhibition?

J. Kastelein, B. Arsenault, Marjorie Boyer, 2015, Current opinion in lipidology.

Particulate air pollution, coronary heart disease and individual risk assessment: a general overview

B. Brunekreef, J. Kastelein, F. Cassee, 2009, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

Metabolic syndrome and risk of restenosis in patients undergoing percutaneous coronary intervention.

A. Zwinderman, R. D. de Winter, J. Kastelein, 2005, Diabetes care.

In Vivo Quantification of Carotid Artery Wall Dimensions: 3.0-Tesla MRI Versus B-Mode Ultrasound Imaging

J. Kastelein, R. J. van der Geest, E. Groot, 2009, Circulation. Cardiovascular imaging.

Determinants of Plaque Progression Despite Very Low Low-Density Lipoprotein–Cholesterol Levels With the PCSK9 Inhibitor, Evolocumab

J. Kastelein, S. Nissen, S. Nicholls, 2021, JACC: Cardiovascular Imaging.

Disease and Chronic Kidney Disease: The TNT (Treating to New Targets) Intensive Lipid Lowering With Atorvastatin in Patients With Coronary Heart

J. Kastelein, P. Deedwania, V. Bittner, 2011 .

Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.

D. Grobbee, P. Thompson, J. Kastelein, 2023, The New England journal of medicine.

Risk of clinical restenosis after PTCA is influenced by a common functional variant in the human stromelysin-1 gene promoter

A. Zwinderman, M. Beekman, J. Kastelein, 1997 .

HDL deficiency and atherosclerosis: lessons from Tangier disease

M. Hayden, J. Kastelein, C. Wellington, 2004, Journal of internal medicine.

Changes in Mipomersen Dosing Regimen Provide Similar Exposure With Improved Tolerability in Randomized Placebo‐Controlled Study of Healthy Volunteers

J. Kastelein, Joann D Flaim, B. Baker, 2014, Journal of the American Heart Association.

Treatment of Low HDL-C Subjects with the CETP Modulator Dalcetrapib Increases Plasma Campesterol Only in Those Without ABCA1 and/or ApoA1 Mutations

J. Kastelein, E. Stroes, D. Bentley, 2014, Lipids.

Adherence to statin treatment in patients with familial hypercholesterolemia: A dynamic prediction model.

J. Kastelein, E. Stroes, M. Hof, 2022, Journal of clinical lipidology.

Current and Future Pharmacologic Options for the Management of Patients Unable to Achieve Low-Density Lipoprotein-Cholesterol Goals with Statins

Erik S. G. Stroes, J. Kastelein, M. Trip, 2008, American journal of cardiovascular drugs : drugs, devices, and other interventions.

Effect of rimonabant on carotid intima–media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial

J. Després, J. Kastelein, D. O'leary, 2011, Heart.

Completeness of carotid intima media thickness measurements depends on body composition: the RADIANCE 1 and 2 trials.

D. Grobbee, J. Kastelein, C. Shear, 2010, Journal of atherosclerosis and thrombosis.

Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study

D. Rader, J. Kastelein, S. Nissen, 2016, European heart journal.

Abstract 17086: Alirocumab LDL-C-Lowering Efficacy in Patients With Moderate CKD

C. Cannon, D. Rader, J. Kastelein, 2015, Circulation.

Combination lipid-lowering therapy as first-line strategy in very high-risk patients.

M. Banach, J. Kastelein, U. Laufs, 2021, European heart journal.

4 metabolic syndrome and risk of restenosis in patients underGoinG percutaneous coronary intervention

A. Zwinderman, R. J. Winter, J. Kastelein, 2006 .

Increased carotid intima-media thickness in HIV patients treated with protease inhibitors as compared to non-nucleoside reverse transcriptase inhibitors.

J. Kastelein, P. Reiss, M. Vogel, 2009, Atherosclerosis.

Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition

J. Kastelein, N. Alp, S. Martin, 2022, European heart journal. Cardiovascular pharmacotherapy.

Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction.

J. Kastelein, A. Lincoff, R. Mehran, 2016, American heart journal.

An integrated evaluation of endothelial constitutive nitric oxide synthase polymorphisms and coronary artery disease in men.

A. Zwinderman, J. Boer, E. Feskens, 2004, Clinical science.

Clinical, diagnostic and therapeutic aspects of (inherited) hypercholesterolemia

J. Kastelein, M. Trip, M. N. Vissers, 2004 .

ATVB IN FOCUS: Emerging Genomic-Based Therapies for Cardiovascular Disease

Benjamin L. Oakes, S. Kathiresan, J. Kastelein, 2023 .

Measuring endothelial glycocalyx dimensions in humans: a potential novel tool to monitor vascular vulnerability

J. Kastelein, M. Nieuwdorp, C. Ince, 2011 .

vulnerabilitya potential novel tool to monitor vascular Measuring endothelial glycocalyx dimensions in

J. Kastelein, M. Nieuwdorp, T. Rabelink, 2015 .

Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial.

D. Mozaffarian, P. Ridker, P. Barter, 2020, JAMA.

Effects of Atorvastatin and Simvastatin on Low-Density Lipoprotein Subtraction Profile, Low-Density Lipoprotein Oxidizability, and Antibodies to Oxidized Low-Density Lipoprotein in Relation to Carotid Intima Media Thickness in Familial Hypercholesterolemia

J. Kastelein, L. V. van Tits, A. Stalenhoef, 2004, Journal of Investigative Medicine.

Familial defective apolipoprotein B and familial hypobetalipoproteinemia in one family: two neutralizing mutations.

J. Kastelein, M. Trip, B. Hutten, 2008, Annals of internal medicine.

Activation of Inflammation and Coagulation After Infusion of C-Reactive Protein in Humans

P. Reitsma, J. Kastelein, E. Stroes, 2005, Circulation research.

Results from a rosuvastatin historical cohort study in more than 45 000 Dutch statin users, a PHARMO study

R. Herings, J. Kastelein, S. Johansson, 2006, Pharmacoepidemiology and drug safety.

Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice.

J. Kastelein, E. Stroes, E. Stroes, 2004, The Netherlands journal of medicine.

Long term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia

M. Prins, J. Kastelein, M. Trip, 2002, Heart.

5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia.

J. Kastelein, T. Rabelink, M. Verhaar, 1998, Circulation.

Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.

P. Barter, J. Kastelein, J. Tardif, 2011, Circulation.

Lipoprotein[a] is not present in the plasma of patients with some peroxisomal disorders.

M. Koschinsky, R. Wanders, J. Kastelein, 1997, Journal of lipid research.

The Spectrum of Statin Therapy in Hyperlipidemic Children

J. Kastelein, M. Trip, J. Kastelein, 2004, Seminars in vascular medicine.

Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study

D. Rader, R. Luben, N. Wareham, 2015, The lancet. Diabetes & endocrinology.

Measuring endothelial glycocalyx dimensions in humans: a potential novel tool to monitor vascular vulnerability.

J. Kastelein, M. Nieuwdorp, M. C. Meuwese, 2008, Journal of applied physiology.

Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study.

R. Luben, N. Wareham, S. Hazen, 2007, Journal of the American College of Cardiology.

UvA-DARE ( Digital Academic Repository ) HDL cholesterol : atherosclerosis and beyond

J. Kastelein, E. Stroes, E. Endert, 2013 .

Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment

Anders G. Olsson, Prakash Deedwania, Michael Gaffney, 2008, Circulation.

The future of best practice.

J. Kastelein, J. Kastelein, 1999, Atherosclerosis.

Cholesteryl Ester Transfer Protein ( CETP ) Inhibition Beyond Raising High-Density Lipoprotein Cholesterol Levels Pathways by Which Modulation of CETP Activity May Alter Atherogenesis

J. Kastelein, S. Boekholdt, E. Stroes, 2006 .

The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group.

J W Jukema, J J Kastelein, A. Zwinderman, 1998, The New England journal of medicine.

Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.

A. Zwinderman, P. Ridker, G. Hitman, 2012, JAMA.

Role of the Apolipoprotein BApolipoprotein A-I Ratio in Cardiovascular Risk Assessment: A CaseControl Analysis in EPIC-Norfolk

A. Zwinderman, M. Sandhu, R. Luben, 2007, Annals of Internal Medicine.

Improving cardiovascular disease prevention : from risk assessment to novel therapy

S. Grundy, P. Barter, J. Kastelein, 2009 .

Increased oxidizability of low-density lipoproteins in hypothyroidism.

W M Wiersinga, T Diekman, P N Demacker, 1998, The Journal of clinical endocrinology and metabolism.

Plasma Levels of Cholesteryl Ester Transfer Protein and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women: The Prospective EPIC (European Prospective Investigation into Cancer and nutrition)–Norfolk Population Study

R. Peters, N. Day, R. Luben, 2004, Circulation.

Combination statin–fibrate therapy: safety aspects

J. Kastelein, E. Stroes, E. Stroes, 2009, Diabetes, obesity & metabolism.

The year in cardiology 2014: prevention.

G. De Backer, J. Kastelein, J. Kastelein, 2015, European heart journal.

Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study.

Nicholas J Wareham, Jan Albert Kuivenhoven, Kay-Tee Khaw, 2007, Journal of the American College of Cardiology.

Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events.

P. Talmud, M. Sandhu, N. Wareham, 2010, Journal of the American College of Cardiology.

LDL Cholesterol Goals in High-Risk Patients: How Low Do We Go and How Do We Get There?

J. Kastelein, J. Kastelein, G. Hovingh, 2013, Drugs.

Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes.

J. Kastelein, D. Waters, J. Kastelein, 2012, Journal of the American College of Cardiology.

Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids.

J. Kastelein, T. Rabelink, M. Verhaar, 1999, Cardiovascular research.

ApoA-I Induction as a Potential Cardioprotective Strategy: Rationale for the SUSTAIN and ASSURE Studies

P. Barter, J. Kastelein, C. Ballantyne, 2012, Cardiovascular Drugs and Therapy.

Cardiovascular metabolic syndrome – an interplay of, obesity, inflammation, diabetes and coronary heart disease

J. Kastelein, J. Jukema, M. Nieuwdorp, 2007, Diabetes, obesity & metabolism.

Enhancing reverse cholesterol transport/raising HDL cholesterol: new options for prevention and treatment of cardiovascular disease.

J. Kastelein, J. Jukema, J. Kastelein, 2004, Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation.

Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients.

P. Libby, P. Ridker, J. Kastelein, 2023, JAMA.

Simvastatin with or without ezetimibe in familial hypercholesterolemia.

A. Zwinderman, D. Gaudet, J. Kastelein, 2008, The New England journal of medicine.

Tetrahydrobiopterin restores endothelial function in hypercholesterolemia.

J. Kastelein, T. Lüscher, T. Rabelink, 1997, The Journal of clinical investigation.

Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial: A Randomized Clinical Trial

J. Kastelein, J. Jukema, W. Koenig, 2018, JAMA cardiology.

In vivo tissue cholesterol efflux is reduced in carriers of a mutation in APOA1[S]

J. Kastelein, J. Kastelein, S. Turner, 2013, Journal of Lipid Research.

Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses.

C. Cannon, M. Taskinen, J. Kastelein, 2019, Journal of clinical lipidology.

Genetic variant of the scavenger receptor BI in humans.

Jan Albert Kuivenhoven, J. Kastelein, J. Kastelein, 2011, The New England journal of medicine.

Effects of oral folic acid supplementation on endothelial function in familial hypercholesterolemia. A randomized placebo-controlled trial.

J. Kastelein, S. Milstien, T. Rabelink, 1999, Circulation.

Two novel mutations in apolipoprotein C3 underlie atheroprotective lipid profiles in families

M. Hayden, J. Kastelein, J. Kastelein, 2014, Clinical genetics.

Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability.

J. Kastelein, J. Kastelein, T. D. de Bruin, 1995, The American journal of cardiology.

Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women.

Nicholas J Wareham, Kay-Tee Khaw, J. Després, 2009, Journal of the American College of Cardiology.

Prevalence and correction of hypothyroidism in a large cohort of patients referred for dyslipidemia.

W. Wiersinga, J. Kastelein, J. Kastelein, 1995, Archives of internal medicine.

Origin and migration of an Afrikaner founder mutation FHAfrikaner-2 (V408M) causing familial hypercholesterolemia.

M. Hayden, J. Kastelein, J. Defesche, 1996, Gene geography : a computerized bulletin on human gene frequencies.

Thermolabile methylenetetrahydrofolate reductase in coronary artery disease.

J. Kastelein, J. Jukema, H. Blom, 1997, Circulation.

Air pollution as noxious environmental factor in the development of cardiovascular disease.

J. Kastelein, M. Cramer, F. Cassee, 2009, The Netherlands journal of medicine.

Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.

J. Kastelein, J. Jukema, W. Koenig, 2014, JAMA.

C-reactive protein is a mediator of cardiovascular disease.

J. Kastelein, S. Boekholdt, E. Stroes, 2010, European heart journal.

The 719Arg Variant of KIF6 and Cardiovascular Outcomes in Statin-Treated, Stable Coronary Patients of the Treating to New Targets and Incremental Decrease in End Points Through Aggressive Lipid-Lowering Prospective Studies

P. Barter, J. Kastelein, D. Waters, 2012, Circulation. Cardiovascular genetics.

Tumor necrosis factor-alpha inhibition protects against endotoxin-induced endothelial glycocalyx perturbation.

J. Kastelein, M. Nieuwdorp, M. C. Meuwese, 2009, Atherosclerosis.

Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial

P. Barter, J. Kastelein, C. Ballantyne, 2016, American Journal of Cardiovascular Drugs.

Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia.

J. Kastelein, M. Trip, E. Veltri, 2008, Journal of the American College of Cardiology.

ABCA1 impacts athero-thrombotic risk and 10-year survival in a contemporary secondary prevention setting.

A. Zwinderman, D. Grobbee, J. Kastelein, 2011, Atherosclerosis.

Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial

J. Kastelein, O. Faergeman, I. Holme, 2009, Journal of internal medicine.

Netherlands with aortic stenosis: a nationwide survey in the Variability in treatment advice for elderly patients

A. Zwinderman, R. Henning, J. Kastelein, 2000 .

ATVB IN FOCUS: Emerging Genomic-Based Therapies for Cardiovascular Disease

Benjamin L. Oakes, S. Kathiresan, J. Kastelein, 2023 .

Thyroid Hormone Mimetics: the Past, Current Status and Future Challenges

J. Kastelein, J. Kastelein, L. Elbers, 2016, Current Atherosclerosis Reports.

Ezetimibe/simvastatin (INEGY™) in the treatment of hyperlipidaemia

J. Kastelein, J. Kastelein, R. Sankatsing, 2005, International journal of clinical practice.

Lipoprotein Lipase Activity Is Associated With Severity of Angina Pectoris

A. Zwinderman, R. Peters, M. Hayden, 2000 .

Lipoprotein lipase activity is decreased in a large cohort of patients with coronary artery disease and is associated with changes in lipids and lipoproteins.

A. Zwinderman, M. Hayden, J. Kastelein, 1999, Journal of lipid research.

Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.

J. Kastelein, P. Deedwania, N. Wenger, 2008, Journal of the American College of Cardiology.

Novel Therapies Focused on the High-Density Lipoprotein Particle

J. Kastelein, J. Kastelein, G. Hovingh, 2014, Circulation research.

Apolipoprotein A-II Is Inversely Associated With Risk of Future Coronary Artery Disease

R. Luben, N. Wareham, J. Kastelein, 2007, Circulation.

Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels.

J. Kastelein, M. Mercuri, J. Kastelein, 2000, The American journal of cardiology.

Recent failures in antiatherosclerotic drug development: examples from the thyroxin receptor agonist, the secretory phospholipase A2 antagonist, and the acyl coenzyme A cholesterol acyltransferase inhibitor programs

J. Kastelein, J. Kastelein, G. Hovingh, 2013, Current opinion in lipidology.

The endothelial glycocalyx: a potential barrier between health and vascular disease

J. Kastelein, M. Nieuwdorp, M. C. Meuwese, 2005, Current opinion in lipidology.

Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study.

R. Luben, N. Wareham, J. Kastelein, 2007, Journal of the American College of Cardiology.

Evidence-based Management of Lipid Disorders

J. Kastelein, E. Stroes, M. N. Vissers, 2010 .

LDL-C-Lowering therapy: Current and future therapeutic targets

J. Kastelein, E. Stroes, M. Visser, 2008, Current cardiology reports.

Reconstituted HDL infusion restores endothelial function in patients with type 2 diabetes mellitus

J. Kastelein, M. Nieuwdorp, T. Rabelink, 2008, Diabetologia.

Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis.

J. Kastelein, S. Boekholdt, E. Stroes, 2006, Arteriosclerosis, thrombosis, and vascular biology.

Endothelial glycocalyx as potential diagnostic and therapeutic target in cardiovascular disease

J. Kastelein, M. Nieuwdorp, E. Stroes, 2009, Current opinion in lipidology.

The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia.

J. Kastelein, J. Kastelein, J. Graaf, 2000, Atherosclerosis.

Lipid-free apolipoprotein (apo) A-I is converted into alpha-migrating high density lipoproteins by lipoprotein-depleted plasma of normolipidemic donors and apo A-I-deficient patients but not of Tangier disease patients.

A. von Eckardstein, J. Kastelein, G. Assmann, 1998, Atherosclerosis.

Ezetimibe stimulates faecal neutral sterol excretion depending on abcg8 function in mice

J. Kastelein, A. Groen, F. Stellaard, 2010, FEBS letters.

Abstract 16531: Decreased Cardiovascular Events in Familial Hypercholesterolemic Patients Treated With Mipomersen, an Antisense Inhibitor of Apolipoprotein B Translation

J. Kastelein, R. Santos, B. Baker, 2014 .

Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial.

M. Eriksson, J. Kastelein, M. Trip, 2010, Clinical therapeutics.

Safety and tolerability of prolonged-release nicotinic acid in statin-treated patients

J. Kastelein, G. Assmann, J. Kastelein, 2007, Current medical research and opinion.

The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial

J. Kastelein, K. Wasilewska, J. E. Cain, 2023, Nature Medicine.

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

P. Libby, P. Pais, J. Varigos, 2017, The Lancet.

Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS)

A. Zwinderman, J. Kastelein, J. Jukema, 2004, European journal of clinical investigation.

C-reactive protein and cholesterol are equally strong predictors of cardiovascular risk and both are important for quality clinical care.

P. Ridker, J. Kastelein, W. Koenig, 2013, European heart journal.

Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial

D. Rader, P. Barter, J. Kastelein, 2015, The Lancet.

Baseline cholesterol absorption and the response to ezetimibe/simvastatin therapy: a post-hoc analysis of the ENHANCE trial[S]

J. Kastelein, B. Hutten, L. Jakulj, 2010, Journal of Lipid Research.

Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial.

B. Williams, G. Bakris, J. Kastelein, 2013, JAMA.

Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia

J. Kastelein, M. Trip, J. Kastelein, 2003, Heart.

Regression of carotid and femoral artery intima-media thickness in familial hypercholesterolemia: treatment with simvastatin.

A. Zwinderman, J. Kastelein, M. Trip, 2003, Archives of internal medicine.

Relationship between atorvastatin dose and the harm caused by torcetrapib

P. Barter, J. Kastelein, C. Shear, 2012, Journal of Lipid Research.

Prolactin fragmentation by trophoblastic matrix metalloproteinases as a possible contributor to peripartum cardiomyopathy and pre-eclampsia.

J. Kastelein, J. V. D. van der Post, M. Cramer, 2010, Medical hypotheses.

Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease.

J. Kastelein, P. Deedwania, A. Breazna, 2008, Mayo Clinic proceedings.

Nonpharmacological lipoprotein apheresis reduces arterial inflammation in familial hypercholesterolemia.

Diederik F Van Wijk, Z. Fayad, J. Kastelein, 2014, Journal of the American College of Cardiology.

SAFETY AND EFFICACY OF LY3015014, A NEW MONOCLONAL ANTIBODY TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) WITH AN INHERENTLY LONGER DURATION OF ACTION, IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA: A RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING, PHASE 2 STUDY

D. Rader, J. Kastelein, S. Nissen, 2015 .